News
Survey aims to raise awareness of the hidden cost of hormonal health
A hormonal health brand is running a survey to raise awareness of ‘The Hidden Cost of Hormonal Health’.
Millions of women struggle with hormonal health conditions, yet too many are left undiagnosed, unheard and unsupported.
MyOva aims to uncover the real cost of living with hormonal health conditions in the UK – financial and emotional.
For many, a diagnosis is only the beginning of the journey.
Women are then left paying for private healthcare, medications and supplements, alternative therapies, time off work, relationships etc. Women are too often left to figure this out alone.
MyOva’s survey aims to raise awareness about the hidden cost of hormonal health conditions, gather real-life data to advocate for better healthcare, and empower more women with knowledge and support.
Leila Martyn is MyOva Founder and a woman who has experienced her own journey with PCOS and multiple miscarriages.
She said: “The hidden cost of hormonal health conditions goes far beyond medical bills- it’s the sick days we push through, the social events we cancel, the confidence we lose, and the sheer mental load of constantly having to advocate for ourselves.
“Too many women are expected to put up with this- to carry on, despite not feeling heard, supported or even taken seriously.
“At MyOva, we hear these stories every day. This survey is about giving women the space to be honest, to be seen, and to finally have their experiences counted.
“Because without real data, the true impact remains invisible – and that needs to change.”
Findings from the survey will highlight areas like how long it took to get a diagnosis for a specific hormonal health condition, the financial cost of diagnosis and treatment, challenges of infertility and miscarriage, effects on relationships and work, and much more.
Find out more and complete the survey here.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Pregnancy
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Fertility2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Wellness3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur6 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health







